Keywords: New Zealand, PHARMAC, GlaxoSmithKline, Tykerb, Votrient, Breast and kidney cancer, Funding

New Zealand to fund new cancer drugs Tykerb and Votrient

Article | 05 March 2012

Print This

The Pharmaceutical Management Agency of New Zealand, PHARMAC, says it is funding two new targeted cancer medicines following an agreement ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in